Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01638676

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

A Phase I/II Trial of Vemurafenib and Metformin to Unresectable Stage IIIC and Stage IV BRAF.V600E+ Melanoma Patients

Sponsor: James Graham Brown Cancer Center

Conditions Melanoma

Updated 8 times since 2017 Last updated: Oct 22, 2021 Started: Jul 31, 2012 Primary completion: Jun 30, 2025 Completion: Jun 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Melanoma, this trial is actively recruiting participants. The trial is conducted by James Graham Brown Cancer Center and has accumulated 8 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Nov 2021 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Unknown Status → Recruiting
Jan 2021 — Nov 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jul 2019 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Jul 2019 [monthly]

Recruiting PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

James Graham Brown Cancer Center
University of Louisville

Data source: University of Louisville

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Louisville, United States